Structure Therapeutics Inc.

GPCR

Explore Our Financial Data > Companies > Structure Therapeutics Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
GPCR
CIK0001888886
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO, CA, 94080
Website structuretx.com
Phone(628) 229-9277
CEORaymond Stevens
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-142.94 million
Net Income$-143.32 million
Net Income to Common$-142.42 million
EPS$-0.86
View All
Balance Sheet
Cash$152.12 million
Assets$866.55 million
Liabilities$41.91 million
Common Equity$824.64 million
Liabilities & Equity$866.55 million
View All
Cash Flow Statement
Net Income$-143.32 million
Cash From Operating Activities$-134.78 million
Cash From Investing Activities$-326.29 million
Cash From Financing Activities$515.37 million
Change in Cash$54.29 million
View All
Calculations
NOPAT$-127.77 million
EBITDA$-201.86 million
Price to EarningsN/A
Price to Book$5.15
ROE-22.85%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025; New preclinical data to be presented at American Diabetes Association (ADA) 85th Scientific Sessions in June 2025 Strong financial position with cash, cash equivalents and short-term investments of $836.9 million SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Stru

Article Link

Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management recently appeared in an interview to express that he thinks small-cap stocks […]

Article Link

Eli Lilly jumps as results from weight-loss pill study rival competitor’s

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). PRIMARY ENDPOINT MET: Eli Lilly anno

Article Link

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

JPMorgan analyst Hardik Parikh says Eli Lilly’s (LLY) Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics (VKTX) could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the ext

Article Link

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the

Article Link